Mesa Laboratories (MLAB) Stock Price, News & Analysis

Company Overview

Mesa Laboratories, Inc. develops, manufactures, and sells quality-control products and services used in healthcare, pharmaceutical, industrial, and other regulated environments. The company’s offerings are designed to help customers monitor processes, verify performance, and maintain compliance with applicable quality and safety requirements.

Mesa Laboratories’ products include biological indicators and other sterilization-assurance products used to evaluate sterilization processes in hospitals, dental practices, laboratories, and pharmaceutical manufacturing. The company also provides radiation-dosimetry products for monitoring occupational exposure, data loggers and environmental-monitoring systems for tracking conditions such as temperature and humidity, and products used in renal-care and dialysis applications.

Founded in 1982 and headquartered in Lakewood, Colorado, Mesa Laboratories serves customers in the United States and international markets through a combination of direct sales and distribution channels. Its products are used across healthcare, life sciences, pharmaceutical manufacturing, and industrial settings where reliable measurement and process validation are important.

Key Stats

• Today's Range: $124.50 to $127.74
• 50-Day Range: $94.64 to $130.65
• 52-Week Range: $63.48 to $132.70
• Volume: 136,667 shs
• Average Volume: 128,086 shs
• Market Capitalization: $708.62 million
• P/E Ratio: 150.64
• Dividend Yield: 0.51%
• Price Target: $110.00
• Consensus Rating: Hold

Mesa Laboratories Stock Analysis - MarketRank™

Mesa Laboratories scored higher than 28% of companies evaluated by MarketBeat, and ranked 761st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Mesa Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and no sell ratings.

Downside Risk

Mesa Laboratories has a consensus price target of $110.00, representing about 13.1% downside from its current price of $126.54.

Amount of Analyst Coverage

Mesa Laboratories has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mesa Laboratories is 150.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.67.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mesa Laboratories is 150.64, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.49.

Price to Book Value per Share Ratio

Mesa Laboratories has a P/B Ratio of 3.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.98% of the float of Mesa Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Mesa Laboratories has a short interest ratio ("days to cover") of 2.72, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mesa Laboratories has recently increased by 28.50%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Mesa Laboratories has a dividend yield of 0.51%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Mesa Laboratories does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Mesa Laboratories is 76.19%. Payout ratios above 75% are not desirable because they may not be sustainable.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Mesa Laboratories has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Mesa Laboratories this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for MLAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.0 / 5
• Insider Trading: Selling Shares

Cluster Insider Buying

2 insiders have purchased shares of Mesa Laboratories in the last three months. Multiple insiders buying is a strong bullish signal.

Insider Buying vs. Insider Selling

In the past three months, Mesa Laboratories insiders have sold 46.04% more of their company's stock than they have bought. Specifically, they have bought $902,411.00 in company stock and sold $1,317,848.00 in company stock.

Percentage Held by Insiders

2.80% of the stock of Mesa Laboratories is held by insiders.

Percentage Held by Institutions

90.60% of the stock of Mesa Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Record date for 9/15 Dividend: 8/31/2026
• Ex-Dividend for 9/15 Dividend: 8/31/2026
• Dividend Payable: 9/15/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:MLAB
• CIK: 724004
• Web: www.mesalabs.com
• Phone: (303) 987-8000
• Fax: 303-987-8989
• Employees: 717
• Year Founded: 1982

Price Target and Rating

• Average Price Target for Mesa Laboratories: $110.00
• High Price Target: $110.00
• Low Price Target: $110.00
• Potential Upside/Downside: -13.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.84
• Trailing P/E Ratio: 150.64
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $6.71 million
• Net Margins: 1.92%
• Pretax Margin: 3.75%
• Return on Equity: 22.72%
• Return on Assets: 9.82%

Debt

• Debt-to-Equity Ratio: 0.73
• Current Ratio: 1.79
• Quick Ratio: 1.32

Sales & Book Value

• Annual Sales: $249.13 million
• Price / Sales: 2.84
• Cash Flow: $11.77 per share
• Price / Cash Flow: 10.75
• Book Value: $33.71 per share
• Price / Book: 3.75

Miscellaneous

• Outstanding Shares: 5,600,000
• Free Float: 5,439,000
• Market Cap: $708.62 million
• Optionable: Not Optionable
• Beta: 0.97